Meeting
2022 ASCO Annual Meeting
PRaG regimens (PD-1 inhibitor combined with radiotherapy and GM-CSF with or not IL-2) rechallenge for patients with acquiring resistance to PD-1/PD-L1 inhibitors in refractory advanced solid tumors.
Authors
Meiling Xu
The Second Affiliated Hospital of Soochow University, Suzhou, China
Meiling Xu , Pengfei Xing , Yuehong Kong , Chenyang Zhang , Xiangrong Zhao , Junjun Zhang , Liyuan Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Clinical Trial Registration Number
ChiCTR1900020175 and NCT04892498
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2601)
DOI
10.1200/JCO.2022.40.16_suppl.2601
Abstract #
2601
Poster Bd #
256
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A prospective, multicenter, single-arm clinical trial of PD-1 inhibitors in combination with radiotherapy and GM-CSF, sequentially followed by IL-2 (PRaG 2.0) therapy in advanced refractory solid tumors.
First Author: Pengfei Xing
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2024 ASCO Annual Meeting
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.
First Author: Yu Chen
Poster
2023 ASCO Annual Meeting
A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.
First Author: Pei Shu